Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Marks, Reinhard  [Clear All Filters]
2023
Gherman R-F, Ewald S, Ihorst G, Strüßmann T, Zeiser R, Wäsch R, Bertz H, Stolz D, Duyster J, Finke J, et al. Identification of clinical factors impacting outcome in patients undergoing autologous hematopoietic cell transplantation after BEAM and TEAM conditioning. Eur J Haematol. 2023.
Apostolova P, Kreutmair S, Toffalori C, Punta M, Unger S, Burk A-C, Wehr C, Maas-Bauer K, Melchinger W, Haring E, et al. Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response. Br J Haematol. 2023.
Thurner L, Ziepert M, Berdel C, Schmidt C, Borchmann P, Kaddu-Mulindwa D, Viardot A, Witzens-Harig M, Dierlamm J, Haenel M, et al. Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study. Hemasphere. 2023;7(7):e904.
Nowakowski GS, Yoon DHyun, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, et al. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large . Ann Hematol. 2023.
Wäsch R, Strüssmann T, Wehr C, Marks R, Meyer PT, Walz G, Engelhardt M. Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis. Ann Hematol. 2023.